Marwah Abdulrahman, Frederik Giesel, Andrew M Scott, Hongcheng Shi, Habib Zaidi, Ahmed Saad Abdlkadir, Sameer Yaser, Ramiz Abuhijlih, Akram Al-Ibraheem
{"title":"Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review.","authors":"Marwah Abdulrahman, Frederik Giesel, Andrew M Scott, Hongcheng Shi, Habib Zaidi, Ahmed Saad Abdlkadir, Sameer Yaser, Ramiz Abuhijlih, Akram Al-Ibraheem","doi":"10.1007/s13139-025-00936-y","DOIUrl":null,"url":null,"abstract":"<p><p>This systematic review evaluates the diagnostic and theranostic utilities of fibroblast activation protein inhibitor (FAPI PET) in patients with soft tissue sarcomas (STS). PubMed, Scopus, and Web of Science were researched for clinical studies employing FAPI PET in STS, covering literature up to October 15, 2024. This review synthesized 36 studies, involving 316 patients and about 30 STS subtypes. Twenty-one case reports highlighted FAPI's diagnostic utility. Comparative analyses often favored FAPI PET/CT over FDG PET/CT for tumor delineation, showing higher SUVmax and tumor-to-background ratios, especially in vascular tumors. Seven original studies consistently reported reliable FAPI uptake metrics across STS subtypes in 253 patients, strongly correlating with FAP immunohistochemistry. FAPI PET/CT generally demonstrated higher uptake, improved accuracy, and better lesion detection than FDG PET/CT, supporting its use in staging and restaging of recurrent and metastatic STS. Eight studies assessed FAPI PET/CT for FAPI-based radioligand therapy (RLT) eligibility, with posttherapeutic outcome predominantly resulted in disease stabilization (16 out of 36 patients), and a favorable safety profile. FAPI PET/CT outperforms FDG in detecting recurrent/metastatic STS, offering higher accuracy in most STS types. FAPI-based radioligand therapy is a promising, safe treatment for challenging STS, with encouraging efficacy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13139-025-00936-y.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"289-305"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446160/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-025-00936-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
This systematic review evaluates the diagnostic and theranostic utilities of fibroblast activation protein inhibitor (FAPI PET) in patients with soft tissue sarcomas (STS). PubMed, Scopus, and Web of Science were researched for clinical studies employing FAPI PET in STS, covering literature up to October 15, 2024. This review synthesized 36 studies, involving 316 patients and about 30 STS subtypes. Twenty-one case reports highlighted FAPI's diagnostic utility. Comparative analyses often favored FAPI PET/CT over FDG PET/CT for tumor delineation, showing higher SUVmax and tumor-to-background ratios, especially in vascular tumors. Seven original studies consistently reported reliable FAPI uptake metrics across STS subtypes in 253 patients, strongly correlating with FAP immunohistochemistry. FAPI PET/CT generally demonstrated higher uptake, improved accuracy, and better lesion detection than FDG PET/CT, supporting its use in staging and restaging of recurrent and metastatic STS. Eight studies assessed FAPI PET/CT for FAPI-based radioligand therapy (RLT) eligibility, with posttherapeutic outcome predominantly resulted in disease stabilization (16 out of 36 patients), and a favorable safety profile. FAPI PET/CT outperforms FDG in detecting recurrent/metastatic STS, offering higher accuracy in most STS types. FAPI-based radioligand therapy is a promising, safe treatment for challenging STS, with encouraging efficacy.
Supplementary information: The online version contains supplementary material available at 10.1007/s13139-025-00936-y.
期刊介绍：
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
